These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

243 related items for PubMed ID: 2534133

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. The effect of plasmacytomas on serum immunoglobulin levels of BALB/c mice.
    Fenton MR, Havas HF.
    J Immunol; 1975 Feb; 114(2 pt 2):793-801. PubMed ID: 1089719
    [Abstract] [Full Text] [Related]

  • 23. Functional activity in vivo of effector T cell populations. II. Anti-tumor activity exhibited by syngeneic anti-MoMULV-specific cytolytic T cell clones.
    Engers HD, Lahaye T, Sorenson GD, Glasebrook AL, Horvath C, Brunner KT.
    J Immunol; 1984 Sep; 133(3):1664-70. PubMed ID: 6205090
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Regression of MOPC 104E plasmacytoma with monoclonal anti-idiotype antibodies.
    Kodama K, Ghanta VK, Hiramoto NS, Hiramoto RN.
    J Biol Response Mod; 1989 Aug; 8(4):385-96. PubMed ID: 2754437
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. The role of L3T4-positive T lymphocytes in the generation of anti-tumor immunity in the mouse.
    Yamamoto H, Takata M, Fujimoto S.
    Jpn J Cancer Res; 1987 Feb; 78(2):176-84. PubMed ID: 2951356
    [Abstract] [Full Text] [Related]

  • 31. Effector mechanism of tumor immunity in murine plasmacytoma.
    Chen YH, Anderson AB.
    Cancer Res; 1988 Mar 15; 48(6):1398-403. PubMed ID: 3257896
    [Abstract] [Full Text] [Related]

  • 32. Importance of timing in cyclophosphamide therapy of MOPC-315 tumor-bearing mice.
    Hengst JC, Mokyr MB, Dray S.
    Cancer Res; 1980 Jul 15; 40(7):2135-41. PubMed ID: 6446379
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Cyclophosphamide-induced immunologically mediated regression of a cyclophosphamide-resistant murine tumor: a consequence of eliminating precursor L3T4+ suppressor T-cells.
    Awwad M, North RJ.
    Cancer Res; 1989 Apr 01; 49(7):1649-54. PubMed ID: 2522344
    [Abstract] [Full Text] [Related]

  • 37. A murine plasmacytoma MOPC 104E resistant to cyclophosphamide is resistant to immunotherapy.
    Satoh K, Kan N, Okino T, Nakanishi M, Mise K, Teramura Y, Yamasaki S, Ohgaki K, Tobe T.
    Cancer Immunol Immunother; 1991 Apr 01; 32(5):273-9. PubMed ID: 1998969
    [Abstract] [Full Text] [Related]

  • 38. Effect of immune response to sheep red blood cells on plasmacytoma MOPC 104 E.
    Ghanta VK, Hiramoto NS, Hiramoto RN.
    Cancer Res; 1981 Jun 01; 41(6):2197-9. PubMed ID: 7237419
    [Abstract] [Full Text] [Related]

  • 39. Host response to myeloma: effect of syngeneic spleen cells on the growth and function of MOPC 104E myeloma in vitro.
    Miura T, Ghanta VK, Hiramoto RN.
    Cancer Invest; 1990 Jun 01; 8(1):17-25. PubMed ID: 2350718
    [Abstract] [Full Text] [Related]

  • 40. Regulation of MOPC 104E by T cells and growth factors induced by C. parvum stimulation.
    Shrestha K, Hiramoto RN, Ghanta VK.
    Int J Cancer; 1984 Jun 15; 33(6):845-50. PubMed ID: 6610653
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.